

---

# Question & Answer and Closing Remarks

**Moderator: Kathleen Moore, MD**

Stephenson Cancer Center, University of Oklahoma

**Ramez Eskander, MD**

University of California, San Diego

**Katherine Fuh, MD, PhD**

University of California, San Francisco

**Antonio González Martín, MD, PhD**

Clínica Universidad de Navarra

# Summary

- Effective and well-tolerated treatments for platinum-sensitive recurrent ovarian cancer remain a substantial medical need, particularly for patients with *BRCA*wt or HRp disease<sup>1</sup>
- Increasing use of bevacizumab and PARP inhibitors in the frontline setting may limit treatment options for patients who progress on PARP inhibitors<sup>2,3</sup>
- Novel treatment strategies, including ADCs, are under investigation to potentially address this unmet need in platinum-sensitive recurrent ovarian cancer<sup>1,4</sup>
- Key properties, such as the linker, payload, target, and DAR, support rational design of ADCs with a wide therapeutic index<sup>4</sup>